CorMedix's (CRMD) DefenCath and Rezzayo medications are expected to drive 2027 growth, in addition to the company's recent acquisition of Heron Therapeutics, Oppenheimer said in a note Friday.
The brokerage said it sees a reset for DefenCath in Q2 2027, to be followed by pricing recovery and improvement through Q4. Reimbursement from Medicare Advantage's contracting terms should drive more durable DefenCath economics, after the add-on period expires in 2029, the brokerage added.
Rezzayo, meanwhile, could open another growth pathway, with a US Food and Drugs Administration's decision on a supplemental new drug application for the prevention of invasive fungal diseases anticipated in Q1, Oppenheimer said. The application has been granted priority review and its approval in Q1 could lead to a launch around mid-2027, Oppenheimer said.
The brokerage also said Heron's acquisition expands CorMedix's commercial revenue base and opportunities, potentially adding $112 million to the group's 2027 sales.
Oppenheimer maintained an outperform rating on CorMedix, with a lower price target of $13 from $15.
Price: 4.85, Change: +0.01, Percent Change: +0.21
Comments